Wegovy semaglutide injection pen: what to know
The Wegovy semaglutide injection pen is a weekly GLP-1 for chronic weight management. See who it is for, the key risks, and access steps.
Key facts
- Semaglutide + B12 is $157/month (billed $157 every 4 weeks), charged only after a clinician approves it.
- Answer a few health questions online. A licensed clinician reviews them. If approved, it ships to your door.
- Adults 18 or older. A licensed clinician reviews your health history and decides whether treatment is appropriate for you. Availability depends on the state you live in.
The Wegovy semaglutide injection pen is a prescription, once-weekly injection used for chronic weight management in certain adults and some adolescents, alongside reduced-calorie diet and increased physical activity. If you are comparing Wegovy with other options, Vitals Vault can help you understand access, safety, and how clinician-guided care works, including compounded semaglutide, which is not the same as the brand product.
- The wegovy semaglutide injection pen is a once-weekly prescription GLP-1 for chronic weight management.
- Wegovy is a brand; compounded semaglutide is different and not FDA-approved.
- Common side effects are stomach-related; serious risks include thyroid tumors, pancreatitis, gallbladder and kidney problems.
- The label lists abdomen, thigh, or upper arm injection sites; get training and follow Instructions for Use.
- Cost depends on coverage rules and availability; current prices may be shown on this page.
What the Wegovy pen is
A prefilled injection pen
Wegovy is a brand name for semaglutide given as a subcutaneous injection using a single-dose, prefilled pen. It is used once weekly on the same day each week, at any time of day, with or without meals. The pen is designed for one injection and then disposal.
What it is approved for
Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and for certain adolescents with obesity. It is used with a reduced-calorie diet and increased physical activity. It is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.
Brand vs compounded semaglutide
Wegovy is a brand product. Compounded semaglutide is prepared by a licensed pharmacy for an individual prescription and is not FDA-approved. It is not a generic of Wegovy, and it may differ in formulation, supply chain, and patient instructions.
What “GLP-1” means
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). GLP-1 is a hormone your body makes that helps regulate appetite and blood sugar after eating. Medicines in this class mimic some of those effects.
How semaglutide works for weight management
Appetite and fullness signals
Semaglutide activates GLP-1 receptors, which can increase feelings of fullness and reduce hunger. For many people, that makes it easier to follow a reduced-calorie eating pattern. Your response can vary, and lifestyle changes remain part of the treatment plan.
Slower stomach emptying
Semaglutide can slow gastric emptying, especially early in treatment. This effect can contribute to nausea and a feeling of being full sooner. It can also affect how quickly some oral medicines are absorbed.
Blood sugar effects
GLP-1 medicines can lower blood sugar by increasing insulin release when glucose is high and reducing glucagon. Even if you do not have diabetes, this is one reason clinicians review your full medication list and medical history before prescribing.
Why titration matters
Wegovy is started at a low dose and increased over time to help reduce side effects, especially nausea and vomiting. Your prescriber sets the schedule and may pause or adjust it based on tolerability and clinical goals.
Who the Wegovy pen may be for
Adults with obesity
Wegovy is indicated for adults with obesity, defined in the label as a body mass index (BMI) of 30 kg/m² or greater, as an adjunct to diet and physical activity. A clinician confirms whether you meet criteria and whether the benefits outweigh the risks for you.
Adults with overweight plus a condition
Wegovy is also indicated for adults with overweight (BMI 27 kg/m² or greater) who have at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia. Your clinician will review your diagnoses and current treatments.
Some adolescents with obesity
Wegovy is indicated for certain adolescents aged 12 years and older with obesity, alongside diet and physical activity. Pediatric use requires careful monitoring for side effects and overall growth and health goals.
Adults with CVD risk reduction
Wegovy is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. This is separate from weight management eligibility and should be discussed with your cardiology or primary care team.
People who want weekly dosing
Some people prefer a once-weekly injection schedule compared with daily medicines. Even with weekly dosing, you still need a plan for follow-up, side effect management, and lifestyle support.
Who should not use Wegovy, or needs extra caution
Certain thyroid cancer history
Wegovy has a boxed warning about thyroid C-cell tumors seen in rodents. Do not use Wegovy if you or a family member has medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Allergy to semaglutide
Do not use Wegovy if you have had a serious hypersensitivity reaction to semaglutide or any of the product components. Seek urgent care for symptoms like swelling of the face, lips, tongue, or throat, or trouble breathing.
History of pancreatitis
Acute pancreatitis has been reported with GLP-1 receptor agonists, including semaglutide. If you have a history of pancreatitis, your clinician may recommend a different approach or closer monitoring.
Gallbladder disease risk
Gallbladder problems, including gallstones, can occur. If you have a history of gallbladder disease or develop symptoms like severe upper abdominal pain, fever, or jaundice, you need prompt medical evaluation.
Kidney problems or dehydration risk
Kidney injury has been reported, sometimes in the setting of nausea, vomiting, or diarrhea that leads to dehydration. If you have chronic kidney disease or take medicines that affect kidney function, your clinician may monitor you more closely.
Pregnancy and breastfeeding
Wegovy is not recommended during pregnancy. If you are planning pregnancy, pregnant, or breastfeeding, discuss safer alternatives and timing with your clinician.
What to expect with the Wegovy pen
A gradual dose increase
Wegovy is titrated upward over several weeks to help your body adjust and to reduce gastrointestinal side effects. Your prescriber may slow the schedule if side effects are hard to tolerate. Do not change your dose schedule without clinician guidance.
Follow-up and monitoring
Clinicians often check in during dose increases to review side effects, hydration, and how you are doing with nutrition and activity. If you have diabetes or take insulin or sulfonylureas, monitoring for low blood sugar can be important.
Injection sites and training
Wegovy is injected under the skin in the abdomen, thigh, or upper arm. A clinician or pharmacist should show you how to use the pen, and the manufacturer’s Instructions for Use provide the full steps and safety checks.
Storage and handling basics
Wegovy pens have specific storage requirements, including refrigeration guidance and limits on time at room temperature. Always follow the label and Instructions for Use, and do not use a pen past its expiration date.
- Route
- Subcutaneous injection (under the skin) via single-dose pen.
- How often
- Once weekly, on the same day each week.
- Injection sites listed
- Abdomen, thigh, or upper arm.
- With food
- Can be taken with or without meals.
Wegovy pen side effects and warnings
Nausea
Nausea is one of the most common side effects and is often most noticeable during dose increases. Eating smaller meals, avoiding high-fat foods, and staying hydrated may help, but persistent vomiting can lead to dehydration and needs medical advice. Tell your clinician if nausea is severe or not improving.
Diarrhea or constipation
Bowel changes are common with semaglutide. Hydration and gradual diet adjustments can help, but severe diarrhea can contribute to dehydration. Contact a clinician if you have persistent symptoms, blood in stool, or signs of dehydration.
Thyroid C-cell tumor warning
Wegovy carries a boxed warning about thyroid C-cell tumors seen in rodents; it is unknown whether this risk applies to humans. Do not use Wegovy if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Report a neck lump, hoarseness, trouble swallowing, or shortness of breath to a clinician.
Pancreatitis
Acute pancreatitis has been reported with semaglutide. Get medical care right away for severe abdominal pain that may radiate to the back, with or without vomiting. If pancreatitis is suspected, clinicians typically stop the medicine and evaluate.
Gallbladder problems
Gallstones and gallbladder inflammation have been reported. Symptoms can include upper abdominal pain, fever, jaundice, or clay-colored stools. These symptoms need prompt medical evaluation.
Kidney injury
Acute kidney injury has been reported, sometimes in people who had nausea, vomiting, or diarrhea leading to dehydration. If you have kidney disease or take diuretics or other kidney-affecting medicines, ask your clinician what monitoring is appropriate. Seek care for reduced urination or severe weakness.
Cost and access: what affects what you pay
Insurance coverage rules
Coverage for Wegovy varies widely by plan and employer. Some plans require prior authorization, documentation of BMI and weight-related conditions, or proof of participation in lifestyle programs. Even with coverage, your out-of-pocket cost can depend on deductibles and pharmacy benefit design.
Supply and pharmacy availability
Availability can vary by dose strength and pharmacy supply. If a pharmacy cannot fill a prescription promptly, your clinician may discuss timing, alternatives, or whether a different GLP-1 is appropriate for your situation.
Brand vs compounded access
Wegovy is a brand product dispensed as the manufacturer’s pen. Compounded semaglutide is prepared by a licensed pharmacy for an individual prescription and is not FDA-approved; it is not a generic of Wegovy. Instructions and supplies can differ between pharmacies.
Where to see current prices
If current prices are available for a treatment option on this page, they are shown in the price block below. Prices can change over time and may not reflect insurance coverage.
How to get Wegovy or a semaglutide plan
- 1
Start with a clinician evaluation
A licensed clinician reviews your health history, current medicines, and goals to decide whether a GLP-1 is appropriate.
- 2
Review labs if needed
A clinician may ask for recent lab results before prescribing, especially if you have diabetes or kidney concerns.
- 3
Discuss options and access
You and your clinician can compare brand Wegovy access, insurance requirements, and alternative GLP-1 medicines.
- 4
Get training and follow-up
If prescribed, a clinician or pharmacist should show you how to use the pen and what side effects to watch for, with ongoing check-ins.
Frequently Asked Questions
How to use wegovy pen?
Wegovy is injected under the skin of the abdomen, thigh, or upper arm, once weekly. A clinician or pharmacist should show you how to use the pen, and the manufacturer’s Instructions for Use provide the full step sequence and safety checks.
How to inject wegovy pen video in stomach?
The label lists the abdomen as an approved injection site, but this page cannot replace hands-on training. Ask your pharmacist or prescribing clinician to demonstrate, and use the official Wegovy Instructions for Use for the exact steps and safety checks.
Is the wegovy semaglutide injection pen the same as compounded semaglutide?
No. Wegovy is a brand product; compounded semaglutide is prepared by a licensed pharmacy for an individual prescription and is not FDA-approved. Compounded semaglutide is not a generic of Wegovy, and instructions and supplies may differ.
What are the most common side effects with the Wegovy pen?
The most common side effects are gastrointestinal, such as nausea, diarrhea, vomiting, constipation, and abdominal pain. Many people notice these most during dose increases, and your clinician can help you plan around hydration and tolerability.
How much does the Wegovy pen cost?
Your cost depends on insurance coverage, prior authorization rules, deductibles, and pharmacy availability. If current prices are available for a treatment option on this page, they are shown in the price block, but your insurance cost may differ.